Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Engels, E. A
Right arrow Articles by Whitby, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Engels, E. A
Right arrow Articles by Whitby, D.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

International Journal of Epidemiology 2002;31:946-950
© International Epidemiological Association 2002


Special Theme: Infectious Diseases

Kaposi’s sarcoma-associated herpesvirus infection in elderly Jews and non-Jews from New York City

Eric A Engelsa, Elizabeth Clarkb,c, Louis M Aledortc, James J Goederta and Denise Whitbyd

a Viral Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.
b Department of Geriatrics and
c Department of Medicine, Mount Sinai Hospital, New York, NY, USA.
d Viral Epidemiology Section, AIDS Vaccine Program, National Cancer Institute-Frederick, Frederick, MD, USA.

Eric A Engels, Viral Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd, EPS 8010, Rockville, MD 20892, USA. E-mail: engelse{at}exchange.nih.gov

Abstract

Background Worldwide, Kaposi’s sarcoma (KS) occurs in immunocompetent elderly adults, especially men. Elderly Jews have relatively high KS risk, but it is unclear whether this indicates heightened prevalence of KS-associated herpesvirus (KSHV), the KS agent. We studied Jewish and non-Jewish patients at a New York City geriatrics clinic.

Methods We measured plasma antibodies against K8.1 (a KSHV glycoprotein) by enzyme immunoassay and against viral latency antigens by immunofluorescence assay. Individuals positive by either were considered KSHV-seropositive. Titres were performed for positive subjects. We used polymerase chain reaction to quantify circulating KSHV DNA.

Results Of 467 subjects (median age 80 years), 40 were KSHV-seropositive (8.6%). Seroprevalence was 8.8% among Jews (18 of 204), similar to other religious groups, and did not differ by sex or region of birth. However, K8.1 antibody titres were higher in men than women (geometric mean titre 177 versus 35, P = 0.03) and increased with age (P = 0.02). The K8.1 titres were higher in three people from Central/Eastern Europe (1280, 1280, 320), all of whom were Jewish, than in others (geometric mean titre 39, P = 0.006). The single person with detectable circulating KSHV (457 copies/million cells) had the highest titre (5120).

Conclusions The KSHV seroprevalence was not elevated among elderly Jews, despite their known high risk for KS. However, among KSHV-seropositive individuals, K8.1 titres were highest in subgroups at greatest risk for KS (men, older individuals, people from Central/Eastern Europe) and may identify individuals with poor immune control of KSHV replication during asymptomatic infection.

Keywords Human herpesvirus 8 (Kaposi’s sarcoma-associated herpesvirus), Kaposi’s sarcoma, aged (elderly), Jews

Accepted 25 March 2002


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.